Date: 2016-01-05
Type of information: Nomination
Compound:
Company: Genticel (France)
Therapeutic area: Infectious diseases - Women health - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 5, 2016, Genticel announced the appointment of a seasoned scientist with broad international experience, Rémi Palmantier, PhD, as Chief Scientific Officer. With over 18 years of biotech and pharmaceutical industry experience, Dr. Palmantier brings to Genticel an in-depth expertise in therapeutic cancer vaccines as well as in other chronic diseases. He joins Genticel from GSK Vaccines, where he was most recently Senior Director, R&D, for the global portfolio of immunotherapies for chronic diseases. Formerly, Dr. Palmantier was Head of Cancer Preclinical Immunotherapies at GSK Biologicals (Canada), and was deeply involved in evaluating external opportunities for licensing to build a portfolio of immunotherapeutic candidates. He started his career with GSK Biologicals in 1997 and held various scientific positions in the Therapeutic Cancer Vaccine Program. Dr. Palmantier has authored multiple scientific publications and is the inventor of over 10 patents with worldwide coverage. He holds a PhD in Immunology from the University of Laval (Canada), and completed a post-doctoral fellowship at the Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA. Marie-Christine Bissery, PhD, Pharm.D, member of Genticel\'s Management Board and previous Chief Scientific Officer, is appointed Chief Development Officer and is responsible for overseeing all project management activities in the Company. With the addition of Rémi Palmantier, an experienced researcher in the field of immunology, in particular in cancer immunotherapy, Genticel expects to accelerate its research and development programs. Dr. Palmantier\'s expertise will facilitate the discovery, development and integration of specific immunotherapies at Genticel. His track record of successfully developing drug candidates will support the Company\'s strategy to expand its pipeline of innovative immunotherapies and to target various types of infectious diseases and cancers, beyond its advanced program of HPV therapeutic vaccines.
Financial terms:
Latest news:
